eo2401,temozolomide,ct041,ipilimumab,nivolumab,bevacizumab
Enterome,orphelia pharma,CARsgen Therapeutics,BMS,Roche
['ca,022,i', 'ca,022,1', 'bevacizumab', 'trigger', 'nivo', 'rosalie study', 'ct041', 'temozolomide', 'rosalie trial', 'eogbm', 'gbm', 'nivolumab', 'eo2401', 'eogbm1-18', 'rosalie', 'heidelberg', 'enterome', 'effector ']
we will present two posters highlighting the promising phase 2 #clinicaldata of our first-in-class #oncomimics peptide-based #immunotherapy, eo2401 on thursday at #esmoimmuno22, the immuno-oncology congress. 
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases.